The stock of InMode Ltd.
INMD,
an Israeli medical tech company, fell 13% early Wednesday, after the company cut its full-year guidance to reflect stronger-than-expected headwinds from the current macro environment, that was causing a slowdown in platform sales, mainly in North America. The company is now expecting adjusted EPS of $2.47 to $2.50, down from prior guidance of $2.53 to $2.57. It expects sales to range from $485 million to $495 million, down from a prior range of $500 million to $510 million. The stock has fallen 34% in the year to date, while the S&P 500
SPX,
has gained 19%.
Read the full article here